Partial federal government shutdown
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
Genomic micro-array and whole exome sequencing
Genomic micro-array and whole exome sequencing (WES) tests may identify, or confirm the presence of chromosome abnormalities.
Status: Decision completed
Why are genomic micro-array and WES being reviewed?
Whether results from genetic sequencing can improve diagnosis, treatment decisions, and health outcomes in some situations remains uncertain.
Primary criteria ranking
- Safety = Medium
- Efficacy = High
- Cost = High
Documentation
| Type | Materials |
|---|---|
| Assessment (2017) |
Assessment timeline
- Draft key questions published: August 16, 2017
- Public comment period: August 16 to August 29, 2017
- Final key questions published: September 14, 2017
- Draft report published: November 9, 2017
- Public comment period: November 9 to December 8, 2017
- Final report published: December 22, 2017
- HTCC public meeting: January 19, 2018